Latest filing published 31 May 2023 for Oramed Pharmaceuticals INC..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Netanel Derovan: trading record in brief
All filings by Netanel Derovan on record concern Oramed Pharmaceuticals Inc., in the capacity of chief executive. The record holds 4 filings, for trades running from 9 January 2022 to 26 May 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 31 May 2023: a share grant, in Oramed Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Netanel Derovan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,500 sharesCommon StockSEC:0001209191-23-033144:0
- 81,000 sharesCommon StockSEC:0001209191-23-024941:0
- 30,000 sharesCommon StockSEC:0001209191-22-043770:0
- 18,000 sharesCommon StockSEC:0001213900-22-001617:0
4 of 4 declarations
